戻る Agenda
Using Legislation to Advance Regulatory Science: "I'm Just a Bill..."
Session Chair(s)
Karen Jaffe
Consultant, United States
Several legislations have been introduced calling for regulatory reform for the drug approval process. FDA is under pressure from industry to enable a regulatory framework for translational medicine but at the same time preserve the public health. This session will discuss impacts to the pharmaceutical industry and investment community as well as the patient community.
Learning Objective : Discuss the issues surrounding introducing legislation; Describe the relationship between legislation and the implementation of regulatory modification; Discuss the impact of legislation on the various stakeholders in the drug development process.
Speaker(s)
Panelist
Juergen Froehlich
Aradigm Corporation, United States
Chief Medical Officer
Panelist
Marc M. Boutin, JD
Novartis , Switzerland
Global Head of Patient Engagement and Advocacy
Panelist
Steven Walker
Abigail Alliance, United States
Co-founder
Panelist
Carla Mann Woods
Fight to Live, United States
CEO and Founder